Thursday, September 16, 2021
AXS-07 for Acute Migraine
On Tuesday September 14th, Axsome Therapeutics announced that the New Drug Application of AXS-07 for acute migraine, has been accepted by the FDA, which has a PDUFA decision date of April 22, 2022. That's great news for the company and migraine sufferers. If approved, we could see the product on the market mid-year 2022.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment